Case Reports in Hematology

Case Reports in Hematology / 2016 / Article

Case Report | Open Access

Volume 2016 |Article ID 7913092 |

Joji Nagasaki, Masahiro Manabe, Kentaro Ido, Hiroyoshi Ichihara, Yasutaka Aoyama, Tadanobu Ohta, Yoshio Furukawa, Atsuko Mugitani, "Postinfluenza Vaccination Idiopathic Thrombocytopenic Purpura in Three Elderly Patients", Case Reports in Hematology, vol. 2016, Article ID 7913092, 4 pages, 2016.

Postinfluenza Vaccination Idiopathic Thrombocytopenic Purpura in Three Elderly Patients

Academic Editor: Gergely Feher
Received25 Nov 2015
Accepted26 Jan 2016
Published21 Feb 2016


The etiologies of secondary idiopathic thrombocytopenic purpura (ITP) include infection, autoimmune disease, and immunodeficiency. We report the cases of three elderly patients who developed ITP after receiving influenza vaccinations. The platelet count of an 81-year-old woman fell to 27,000/μL after she received an influenza vaccination. A 75-year-old woman developed thrombocytopenia (5,000 platelets/μL) after receiving an influenza vaccination. An 87-year-old woman whose laboratory test values included a platelet count of 2,000/μL experienced genital bleeding after receiving an influenza vaccination. After Helicobacter pylori (HP) eradication or corticosteroid treatment, all of the patients’ platelet counts increased. Influenza vaccination is an underlying etiology of ITP in elderly patients. HP eradication or corticosteroid treatment is effective for these patients. Clinicians should be aware of the association between ITP and influenza vaccinations.

1. Introduction

Idiopathic thrombocytopenic purpura (ITP) is an acquired form of thrombocytopenia caused by autoantibody-mediated platelet destruction. The exact cause of ITP is unknown. It is initially treated with corticosteroids, intravenous immunoglobulin (IVIG), or intravenous anti-D immunoglobulin (IV anti-D). Corticosteroids are commonly recognized as a first-line therapy for acute ITP in adult patients. IVIG and IV anti-D are used for patients who need a rapid platelet increase or have a contraindication for corticosteroids. Although these treatments are effective and indispensable, the existence of treatment-related adverse events should be noted, especially in elderly patients. Here we report three elderly patients with ITP who had recently received influenza vaccinations. Their platelet counts increased after eradication of Helicobacter pylori (HP) or treatment with a corticosteroid.

2. Case Reports

2.1. Case 1

An 81-year-old woman whose platelet count was 184,000/μL 3 months before admission was referred to our hospital because of thrombocytopenia. Her platelet count reduction was found unexpectedly during a medical examination; she had no symptoms caused by thrombocytopenia. She had received an influenza vaccination 4 weeks before developing thrombocytopenia. Her laboratory data at the time of thrombocytopenia diagnosis were as follows: platelet count, 39,000/μL; white blood cell count, 4,900/μL without atypical cells; hemoglobin concentration, 14.1 g/dL; and platelet-associated IgG (PAIgG), 97 ng/107 cells. Bone marrow was normocellular; the megakaryocyte count was 56/μL. A urea breath test for HP was positive. The patient was diagnosed with ITP. HP was eradicated with 400 mg of clarithromycin, 1,500 mg of amoxicillin hydrate, and 20 mg of rabeprazole per day for 7 days. The patient’s platelet count gradually increased and within 5 months had normalized. The patient’s platelet count has remained within the reference range for over 2 years.

2.2. Case 2

A 75-year-old woman received an influenza vaccination; her platelet count measured the same day was 251,000/μL. Five weeks after the vaccination, she was referred to our hospital because of thrombocytopenia with purpura combined with gingival and nasal hemorrhaging. Her laboratory data at admission were as follows: platelet count, 5,000/μL; white blood cell count, 10,600/μL without atypical cells; hemoglobin concentration, 15.9 g/dL; and PAIgG, 3780 ng/107 cells. Bone marrow was normocellular. A urea breath test for HP was positive and a diagnosis of ITP was established. She experienced massive bleeding because of marked thrombocytopenia; hence, we started HP eradication as well as steroid treatment (1 mg/kg of prednisolone per day). Four weeks after the initiation of treatment, her platelet count had increased to within the normal range, so the steroid treatment was gradually tapered off over 2 months. No evidence of relapsed thrombocytopenia has been seen for over 15 months.

2.3. Case 3

An 87-year-old woman who showed no signs of platelet reduction such as purpura received an influenza vaccination. Two weeks after the vaccination, she was referred to us because of genital bleeding and purpura. Her laboratory data on admission were as follows: platelet count, 2,000/μL; white blood cell count, 9,200/μL without atypical cells; hemoglobin concentration, 9.3 g/dL; and PAIgG, 950 ng/107 cells. The bone marrow megakaryocyte count was 111/μL. We diagnosed the patient with ITP and began treatment with 1 mg/kg of prednisolone per day. The steroid treatment resulted in a rapid increase in the patient’s platelet count, so it was tapered off over several months. The patient exhibited no evidence of relapsed thrombocytopenia after treatment.

3. Discussion

These cases illustrate two facts: influenza vaccination caused ITP in three elderly patients, and HP eradication and/or corticosteroid administration may effectively treat postinfluenza vaccination ITP in elderly patients.

ITP is associated with several types of vaccinations. In previous studies, the risk of developing ITP increased after administration of measles-mumps-rubella (MMR), some together with MMR, hepatitis A, varicella, and diphtheria-tetanus-pertussis vaccines in children and adolescents [12]. Adjuvants, which are compounds incorporated into vaccines to enhance immunogenicity, have been implicated in autoimmune/inflammatory syndrome induced by adjuvants (ASIA) [13]. Although thrombocytopenia can also be seen in ASIA patients, the association between ITP and influenza vaccination is still unclear. A number of case-control studies and case reports concerning postinfluenza vaccination ITP have been published (Table 1) [111, 14]. The Berlin Case-Control Surveillance Study of drug-associated ITP concluded that influenza vaccinations increase the risk of ITP. Twelve cases of postinfluenza vaccination ITP, including our three, have been reported. Features common to most reported cases include PAIgG elevation, time from vaccination to development of ITP, and treatment response.

Study designReferenceNumber of ITP patientsPatient characteristicsHistoryDuration of thrombocytopenia from vaccinationPlatelet count (/μL)Elevation of PAIgG levelTreatmentOutcome

Case-control study Jadavji et al., 2003 [1]2NANA10 days
14 days
Garbe et al., 2012 [14]3 NANANANANANANA
Grimaldi-Bensouda et al., 2012 [2]43NANA<12 moNANANANA

Case reportKelton, 1981 [3]1 38-year-old, maleCOPD12 days32000PositiveSteroidsFR
Casoli and Tumiati, 1989 [4]132-year-old, maleNone15 daysNANASteroidsFR
Granier et al., 2003 [5]1 72-year-old, femaleNone8 days3000PositiveSteroidsFR
Ikegame et al., 2006 [6]119-year-old, femaleALL (post-BMT)14 days10000PositiveIVIG, steroids, and eradicationFR
Tishler et al., 2006 [7]1 68-year-old, maleHT14 days3000NAIVIG and steroidsFR
Mamori et al., 2008 [8]175-year-old, femaleAILD7 days5000PositiveSteroidsFR
Tsuji et al., 2009 [9]179-year-old, maleDM4 days4000NegativeIVIG and steroidsc-ITP
Mantadakis et al., 2010 [10]13-year-old, maleNone26 days11000NAIVIGFR
Shlamovitz and Johar, 2013 [11]1 50-year-old, manNone4 days<5000NAIVIG and steroidsFR
81-year-old, femaleHT28 days27000Positive EradicationFR
Nagasaki 2016375-year-old, femaleAP and LD35 days5000Positive Steroids and eradicationFR
87-year-old, femaleNone14 days2000Positive SteroidsFR

ITP: immune thrombocytopenic purpura; NA: not applicable; COPD: chronic obstructive pulmonary disease; ALL: acute lymphoblastic leukemia; BMT: bone marrow transplantation; HT: hypertension; AILD: autoimmune liver disease; DM: diabetes mellitus; HL: hyperlipidemia; AP: angina pectoris; IVIG: intravenous immunoglobulin; FR: full recovery; c-ITP: chronic-ITP.

All of our patients and most patients in previous reports had PAIgG elevations. PAIgG can detect both surface IgG and α-granule IgG following platelet lysis [15]. Vaccine-associated ITP is probably caused by molecular mimicry, which involves the activation of autoreactive B or T cells by peptides in the vaccine that exhibit structural similarity to antigens found on platelets [12]. Elevated PAIgG may be an antibody produced by molecular mimicry.

Two of our patients developed ITP within 4 weeks after influenza vaccination and the third within 5 weeks. In previous patient reports, postinfluenza vaccination ITP developed 4–26 days after vaccination. This variability may depend on the patient’s influenza antibody status. Some patients may have preexisting antibodies from prior influenza vaccines, some may be mounting an anamnestic response to a previously encountered antigen, and others may be undergoing primary alloimmunization because they had no previous exposure to the antigen [16]. An anamnestic response occurs in 3–10 days. Primary alloimmunization requires at least 2-3 weeks. Therefore, postinfluenza vaccination ITP in elderly patients may occur within several days or 2-3 weeks after vaccination.

In a previous report, elderly patients with ITP had a response rate of about 60% and were likely to relapse after treatment (31.3% of patients relapsed) [17]. In previously reported cases of postinfluenza vaccination ITP, 8 of 9 patients made a full recovery (Table 1). All three of our patients also achieved platelet recovery and were stable after treatment. Therefore, postinfluenza vaccination ITP in elderly patients may respond to treatment.

MMR vaccine is associated with the development of ITP in children [18]. The clinical features are similar to those of postinfluenza vaccination ITP. Signs usually occur within 6 weeks after vaccination [19], and more than 90% of patients recover from thrombocytopenia within 6 months after diagnosis [20]. In contrast to post-MMR vaccination ITP, 7 of the 12 reported postinfluenza vaccination ITP patients were elderly (Table 1), possibly because influenza vaccinations are recommended for elderly patients. ITP is likely to be found in elderly patients because they exhibit bleeding symptoms more frequently [21]. Two of our three patients with ITP were admitted to the hospital with bleeding symptoms.

HP eradication, corticosteroid administration, or both may effectively treat postinfluenza vaccination ITP in elderly patients. Prednisone, IVIG, and IV anti-D are recommended general treatments for ITP patients with severe thrombocytopenia or bleeding [22]. The rate of treatment-related adverse events, such as IVIG-related acute renal failure and steroid-induced diabetes or infection, is higher in elderly than in young patients with ITP [21]. Our patients’ platelet counts increased smoothly without the use of IVIG and with no adverse events. One patient achieved full recovery and long-term remission with HP eradication only. We treated two patients with corticosteroids because of their bleeding symptoms. Post-MMR vaccination ITP is associated with a shorter duration of thrombocytopenia and less severe bleeding than is primary ITP [20]. For patients with postinfluenza vaccination ITP as well as those with primary ITP, corticosteroids and HP eradication may be effective treatments. HP eradication may be an effective and safe treatment for elderly patients with postinfluenza vaccination ITP, especially those without severe bleeding.

In conclusion, while influenza vaccinations are useful for preventing influenza infections and their complications, clinicians should be aware that an association with ITP is strongly suspected.

Conflict of Interests

The authors declare that there is no conflict of interests regarding the publication of this paper.


  1. T. Jadavji, D. Scheifele, and S. Halpein, “Thrombocytopenia after immunization of Canadian children, 1992 to 2001,” The Pediatric Infectious Disease Journal, vol. 22, no. 2, pp. 119–122, 2003. View at: Google Scholar
  2. L. Grimaldi-Bensouda, M. Michel, E. Aubrun et al., “A case–control study to assess the risk of immune thrombocytopenia associated with vaccines,” Blood, vol. 120, no. 25, pp. 4938–4944, 2012. View at: Publisher Site | Google Scholar
  3. J. G. Kelton, “Vaccination–associated relapse of immune thrombocytopenia,” The Journal of the American Medical Association, vol. 245, no. 4, pp. 369–370, 1981. View at: Publisher Site | Google Scholar
  4. P. Casoli and B. Tumiati, “Acute idiopathic thrombocytopenic purpura after anti-influenza vaccination,” Medicina, vol. 9, pp. 417–418, 1989 (Italian). View at: Google Scholar
  5. H. Granier, X. Nicolas, J.-P. Laborde, and F. Talarmin, “Severe autoimmune thrombopenia following anti–influenza vaccination,” Presse Medicale, vol. 32, no. 26, pp. 1223–1224, 2003 (French). View at: Google Scholar
  6. K. Ikegame, K. Kaida, T. Fujioka et al., “Idiopathic thrombocytopenic purpura after influenza vaccination in a bone marrow transplantation recipient,” Bone Marrow Transplantation, vol. 38, no. 4, pp. 323–324, 2006. View at: Publisher Site | Google Scholar
  7. M. Tishler, O. Levy, and M. Amit-Vazina, “Immune thrombocytopenic purpura following influenza vaccination,” Israel Medical Association Journal, vol. 8, no. 5, pp. 322–323, 2006. View at: Google Scholar
  8. S. Mamori, K. Amano, H. Kijima, I. Takagi, and H. Tajiri, “Thrombocytopenic purpura after the administration of an influenza vaccine in a patient with autoimmune liver disease,” Digestion, vol. 77, no. 3-4, pp. 159–160, 2008. View at: Publisher Site | Google Scholar
  9. T. Tsuji, H. Yamasaki, and H. Tsuda, “Refractory idiopathic thrombocytopenic purpura following influenza vaccination,” Rinshō Ketsueki, vol. 50, no. 7, pp. 577–579, 2009 (Japanese). View at: Google Scholar
  10. E. Mantadakis, E. Farmaki, S. Thomaidis, A. Tsalkidis, and A. Chatzimichael, “A case of immune thrombocytopenic purpura after influenza vaccination: consequence or coincidence?” Journal of Pediatric Hematology/Oncology, vol. 32, no. 6, pp. e227–e229, 2010. View at: Publisher Site | Google Scholar
  11. G. Z. Shlamovitz and S. Johar, “A case of Evans' syndrome following influenza vaccine,” Journal of Emergency Medicine, vol. 44, no. 2, pp. e149–e151, 2013. View at: Publisher Site | Google Scholar
  12. M. Rinaldi, C. Perricone, O.-D. Ortega-Hernandez, R. Perricone, and Y. Shoenfeld, “Immune thrombocytopaenic purpura: an autoimmune cross–link between infections and vaccines,” Lupus, vol. 23, no. 6, pp. 554–567, 2014. View at: Publisher Site | Google Scholar
  13. P. Pellegrino, E. Clementi, and S. Radice, “On vaccin's adjjuvants and autoimmunity—current evidence and future perspectives,” Autoimmunity Reviews, vol. 14, pp. 880–888, 2015. View at: Google Scholar
  14. E. Garbe, F. Andersohn, E. Bronder et al., “Drug-induced immune thrombocytopaenia: results from the Berlin Case-Control Surveillance Study,” European Journal of Clinical Pharmacology, vol. 68, no. 5, pp. 821–832, 2012. View at: Publisher Site | Google Scholar
  15. J. N. George, “Platelet immunoglobulin G: its significance for the evaluation of thrombocytopenia and for understanding the origin of α-granule proteins,” Blood, vol. 76, no. 5, pp. 859–870, 1990. View at: Google Scholar
  16. B. Kenney and G. Stack, “Drug-induced thrombocytopenia,” Archives of Pathology and Laboratory Medicine, vol. 133, no. 2, pp. 309–314, 2009. View at: Google Scholar
  17. H. Zhou, R. Fu, H. Wang et al., “Immune thrombocytopenia in the elderly: clinical course in 525 patients from a single center in China,” Annals of Hematology, vol. 92, no. 1, pp. 79–87, 2013. View at: Publisher Site | Google Scholar
  18. V. Cecinati, N. Principi, L. Brescia, P. Giordano, and S. Esposito, “Vaccine administration and the development of immune thrombocytopenic purpura in children,” Human Vaccines & Immunotherapeutics, vol. 9, no. 5, pp. 1158–1162, 2013. View at: Publisher Site | Google Scholar
  19. T. Jefferson, D. Price, V. Demicheli, and E. Bianco, “Unintended events following immunization with MMR: a systematic review,” Vaccine, vol. 21, no. 25-26, pp. 4135–4136, 2004. View at: Publisher Site | Google Scholar
  20. V. Cecinati, N. Principi, L. Brescia, P. Giordano, and S. Esposito, “Vaccine administration and the development of immune thrombocytopenic purpura in children,” Human Vaccines and Immunotherapeutics, vol. 9, no. 5, pp. 1158–1162, 2013. View at: Publisher Site | Google Scholar
  21. M. Michel, O. B. Rauzy, F. R. Thoraval et al., “Characteristics and outcome of immune thrombocytopenia in elderly: results from a single center case-controlled study,” American Journal of Hematology, vol. 86, no. 12, pp. 980–984, 2011. View at: Publisher Site | Google Scholar
  22. D. B. Cines and J. B. Bussel, “How I treat idiopathic thrombocytopenic purpura (ITP),” Blood, vol. 106, no. 7, pp. 2244–2251, 2005. View at: Publisher Site | Google Scholar

Copyright © 2016 Joji Nagasaki et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

More related articles

 PDF Download Citation Citation
 Download other formatsMore
 Order printed copiesOrder

Related articles